TERUMO BCT, INC.

Lobbying for TERUMO BCT, INC. · Medical technology company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$20,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Colorado

Official filing document

Government bodies contacted 3

Bureau of Industry and Security (BIS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

S 752
Accelerating Kids’ Access to Care Act
HR 1509
Accelerating Kids’ Access to Care Act of 2025
S 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Lobbying activity 2

Trade (domestic/foreign)

Global trade and tariffs

Health Issues

S.752/H.R.1509 - Accelerating Kids Access to Care Act S.735/H.R. 1796 - Reauthorization of Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 Blood and cell collection, storage, and processing Blood donation supply and quality

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.